• 1
    Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37: 23842.
  • 2
    Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JB, Silverman NH, et al. Maternal anti-Ro and anti-La antibody– associated endocardial fibroelastosis. Circulation 2002; 105: 8438.
  • 3
    Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 18325.
  • 4
    Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120: 54451.
  • 5
    Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 165866.
  • 6
    Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al, for the PRIDE Investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block. The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 48593.
  • 7
    Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti–SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 125361.
  • 8
    Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti SSA/Ro-SSB/La antibodies. Lupus 2002; 11: 14551.
  • 9
    Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137: 67480.
  • 10
    Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 3: 24807.
  • 11
    Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 123341.
  • 12
    Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, et al. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005; 52: 307986.
  • 13
    Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008; 154: 307.
  • 14
    Buyon JP, Winchester RJ, Slade SG, Arnett F, Copel J, Friedman D, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children: comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti–SS-A/Ro and anti–SS-B/La antibodies. Arthritis Rheum 1993; 36: 126373.
  • 15
    Tseng CE, Caldwell K, Feit S, Chan EK, Buyon JP. Subclass distribution of maternal and neonatal anti-Ro (SSA) and La (SSB) antibodies in congenital heart block. J Rheumatol 1996; 23: 92532.
  • 16
    Donald A, Donner A. Adjustments to the Mantel-Haenszel chi-square statistic and odds ratio variance estimator when the data are clustered [published erratum appears in Stat Med 1997;16:2927–8]. Stat Med 1987; 6: 4919.
  • 17
    Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, Wechsler B, Vauthier D, Ghillani P, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62: 10102.
  • 18
    Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999; 93: 9527.
  • 19
    Buyon JP, Slade SG, Reveille JD, Hamel JC, Chan EK. Autoantibody responses to the “native” 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjögren's syndrome. J Immunol 1994; 152: 367584.
  • 20
    Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum 2001; 44: 4878.
  • 21
    Srinivasan S, Strasburger J. Overview of fetal arrhythmias. Curr Opin Pediatr 2008; 20; 52231.
  • 22
    Gladman G, Silverman ED, Yuk-Law, Luy L, Boutin C, Laskin C, et al. Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol 2002; 19: 7380.
  • 23
    Solomon DG, Rupel A, Buyon JP. Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus 2003; 12: 6467.
  • 24
    Friedman DM, Rupel A, Buyon JP. Epidemiology, etiology, detection and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007; 9: 1018.
  • 25
    Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am 2007; 33: 26785.
  • 26
    Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjögren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 1208.
  • 27
    Harmon CE, Lee LA, Huff JC, Norris DA, Weston WL. The frequency of autoantibodies to the SS-A/Ro antigen in pregnancy sera [abstract]. Arthritis Rheum 1984; 27 Suppl 4: S20.
  • 28
    Siren MK, Julkunen H, Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol 1998; 25: 18624.
  • 29
    Clancy RM, Backer CB, Yin X, Kapur RP, Molad Y, Buyon JP. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-α and TGF-β1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 2003; 171: 325361.